Glasgow, United Kingdom, April 13th 2015 – Clyde Biosciences Ltd. (Clyde Biosciences) has announced a £2 million ‘Series A’ investment led by Epidarex Capital, a
Apellis’ CEO, Cedric Francois, outlines the company thoughts regarding the emergence of immunotherapy as a therapeutic approach that focuses on correcting the underlying immune dysregulation rather
Brighton, Sussex, February 11th 2015 – ENTERPRISE THERAPEUTICS Ltd, a drug discovery company focused on new therapeutics for respiratory diseases, today announced that it has
Crestwood, KY – February 10th 2015 – Apellis Pharmaceuticals, Inc. announced that it has begun the Phase I clinical trial of its drug compound APL-2
By Scott Dance, The Baltimore Sun Within a year and a half of launching as a startup, Harpoon Medical’s heart surgery device could be used
Crestwood, KY – December 2nd 2014 – Apellis Pharmaceuticals, Inc., a leading biotechnology company applying immunotherapy to autoimmune disease, today announced that it has completed
EDINBURGH, UK, December 2, 2014 – SIRAKOSS, an innovative medical device company based in Edinburgh and Aberdeen today announced it has secured $4.8m (£3.1m) in
CRESTWOOD, KY November 20, 2014 – Apellis Pharmaceuticals Inc. Complement inhibition is the only mechanism thus far to show reductions in the growth of dry
October, 2014 – Epidarex is a specialist life science venture capital group that recently raised a new fund of £47.5 million dedicated to UK start
Epidarex Capital, a leading international venture capital firm, has raised over £47.5 million to lead investments in early-stage life science and health technology companies, including